Todd A. Huffman
Founder at Padlock Therapeutics, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Michael Gilman | M | 69 |
Padlock Therapeutics, Inc.
 Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | 10 years |
| Kerri Mowen | M | - |
Padlock Therapeutics, Inc.
Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | 10 years |
| James R. Andrews | M | 82 |
The University of Virginia School of Medicine
| - |
| Elizabeth L. Anderson | M | 83 |
University of Virginia
| 19 years |
| David Grainger | M | 58 |
Padlock Therapeutics, Inc.
Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | - |
| Kevin R. Lynch | M | - |
The University of Virginia School of Medicine
| - |
| Roel Bulthuis | M | - |
Padlock Therapeutics, Inc.
Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | 10 years |
| Michael Gladstone | M | 37 |
Padlock Therapeutics, Inc.
Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | - |
| Marian Nakada | M | - |
Padlock Therapeutics, Inc.
Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | - |
| Paul Thompson | M | - |
Padlock Therapeutics, Inc.
Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | - |
| Rab Prinjha | M | - |
Padlock Therapeutics, Inc.
Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | - |
| Nathan Fountain | M | 61 |
The University of Virginia School of Medicine
| - |
| Linda Duska | F | - |
The University of Virginia School of Medicine
| - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Ryan Berg | M | - |
University of Virginia
| 10 years |
| Adam Fassnacht | M | - |
University of Virginia
| 6 years |
| Rahul Gorawara | M | - |
University of Virginia
| 5 years |
| Zachary Bratun Glennon | M | - |
University of Virginia
| 4 years |
| Alexander T. Seals | M | - |
University of Virginia
| 5 years |
| Francis Teo | M | - |
University of Virginia
| 6 years |
| Edward Shuman | M | - |
University of Virginia
| 9 years |
| Scott B Crenshaw | M | - |
University of Virginia
| 6 years |
| Kevin Matthew Mixon | M | - |
University of Virginia
| 4 years |
| Howard Hechler | M | - |
University of Virginia
| 4 years |
| Max Leykin | M | - |
University of Virginia
| 5 years |
| Chris Carroll | M | - |
University of Virginia
| 4 years |
| Linda S. Tansik | F | - |
RCT BioVentures
 RCT BioVentures Investment ManagersFinance RCT BioVentures (RCT BioVentures) is a venture capital subsidiary of Research Corporation Technologies Inc founded in 1987. The firm is headquartered in Tucson, Arizona. | 26 years |
| Nitin Chandra | M | - |
University of Virginia
| 9 years |
| McGavock Dickinson Dunbar | M | - |
University of Virginia
| 4 years |
| Kristina Wilmer | F | - |
University of Virginia
| 7 years |
| Ryan Gurney | M | - |
University of Virginia
| 4 years |
| Brock Saunders | M | - |
University of Virginia
| 4 years |
| William DeVar | M | - |
University of Virginia
| 4 years |
| Nick Harris | M | - |
University of Virginia
| 4 years |
| Alan Lawrence Broderick | M | - |
University of Virginia
| 4 years |
| Tracy Schwartz-Ward | F | - |
University of Virginia
| 4 years |
| Richard Middleton Williamson | M | - |
University of Virginia
| 4 years |
| Erhan Artuc | M | - |
University of Virginia
| 3 years |
| Viraj Didwania | M | - |
University of Virginia
| 4 years |
| Chen Feng Song | M | 42 |
University of Virginia
| 4 years |
| David Seaman | M | - |
University of Virginia
| 10 years |
| Zachary F. Hill | M | - |
University of Virginia
| 4 years |
| Ethan James Appleby | M | - |
University of Virginia
| 4 years |
| Harrison Segall | M | - |
University of Virginia
| 4 years |
| William Flood | M | - |
University of Virginia
| 3 years |
| Brian Fairbank | M | - |
University of Virginia
| 4 years |
| Tarapore Shahrukh | M | - |
University of Virginia
| 2 years |
| Geoffrey Miles | M | - |
University of Virginia
| 4 years |
| Diane Banta | F | - |
University of Virginia
| 4 years |
| Hanny Akl | M | - |
University of Virginia
| 1 years |
| Christos Tsentas | M | 37 |
University of Virginia
| 4 years |
| Thaddeus Darden | M | 37 |
University of Virginia
| 4 years |
| Dave Olsen | M | - |
University of Virginia
| 1 years |
| Ryan Grammer | M | - |
University of Virginia
| 4 years |
| Rachel Kropa | F | - |
University of Virginia
| 4 years |
| Ed Cao | M | - |
University of Virginia
| 4 years |
| Lauren Nanna | F | - |
University of Virginia
| 4 years |
| James Edward Bogart | M | - |
University of Virginia
| 4 years |
| Jackie Dunklau | F | - |
University of Virginia
| 4 years |
| Francis Nathaniel Gotianun | M | 40 |
University of Virginia
| 4 years |
| Mesh Lakhani | M | - |
University of Virginia
| 4 years |
| Srikripa Devarakonda | M | - |
University of Virginia
| 6 years |
| Jed Leidheiser | M | - |
University of Virginia
| 4 years |
| Guido DeAscanis | M | - |
University of Virginia
| 2 years |
| Jonathan Chou | M | - |
University of Virginia
| 4 years |
| Seanan Maranzano | M | - |
University of Virginia
| 4 years |
| Tyler Walk | M | - |
University of Virginia
| 4 years |
| Jaime Forsyth | F | - |
University of Virginia
| 4 years |
| Christopher C. Green | M | - |
University of Virginia
| 3 years |
| Peter Chidyllo | M | - |
University of Virginia
| 4 years |
| Daniel Lawrence | M | - |
University of Virginia
| 4 years |
| Scott B. Luftglass | M | - |
University of Virginia
| 3 years |
| Louise M. Bald | F | - |
University of Virginia
| 4 years |
| Chad Ellis | M | - |
University of Virginia
| 4 years |
| John L. Gainer | M | 85 |
University of Virginia
| 39 years |
| David Lonergan | M | - |
RCT BioVentures
RCT BioVentures Investment ManagersFinance RCT BioVentures (RCT BioVentures) is a venture capital subsidiary of Research Corporation Technologies Inc founded in 1987. The firm is headquartered in Tucson, Arizona. | 2 years |
| Cody Nystrom | F | - |
University of Virginia
| 4 years |
| Philip Giampietro | M | - |
University of Virginia
| 4 years |
| Michael F. Farah | M | - |
University of Virginia
| 4 years |
| Matthew Mariner | M | - |
University of Virginia
| 4 years |
| Kenneth Rollins | M | - |
University of Virginia
| 3 years |
| Rosemary Liu | F | - |
University of Virginia
| 4 years |
| Zhi Xiong Yan | M | 53 |
University of Virginia
| 2 years |
| Noah Charles Perry Greenbaum | M | - |
University of Virginia
| 4 years |
| David Proman | M | 41 |
University of Virginia
| 4 years |
| Kenneth Suggett George | M | - |
University of Virginia
| 4 years |
| Brad Sullivan | M | - |
University of Virginia
| 2 years |
| Bradford James Manning | M | - |
University of Virginia
| 4 years |
| Evan Ufer | M | - |
University of Virginia
| 4 years |
| Ross Baird | M | - |
University of Virginia
| 4 years |
| Michael Koban | M | - |
University of Virginia
| 4 years |
| Brian Welsh | M | - |
University of Virginia
| 4 years |
| James Aldige | M | - |
University of Virginia
| 4 years |
| Ali Houshmand | M | - |
University of Virginia
| 2 years |
| Daniel Hayden Saunders | M | - |
University of Virginia
| 4 years |
| Yumee Song | F | - |
University of Virginia
| 4 years |
| Teddy Lamade | M | - |
University of Virginia
| 4 years |
| Justin P. Lux | M | - |
University of Virginia
| 4 years |
| Pike Howard | M | - |
University of Virginia
| 4 years |
| Jagjit Idnani | M | - |
University of Virginia
| 4 years |
| Louis Matthews | M | - |
University of Virginia
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 96 | 96.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Todd A. Huffman
- Personal Network
